Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience

Abstract

Of the enrolled subjects, 71% were women and 29% were men. Based on POEM 18% had mild, 50% moderate and 22% severe AD. Based on the EASI score 42% were classified as mild, 27% as moderate and 7% as severe. Three per cent had clear skin, and 20% had almost clear skin based on EASI score. (Table 1).Thornton et al. 3 showed that the cost per retained participant in 24 studies recruited through Facebook was between $1.36 and $110. The costs in our study were in the higher end probably due to the geographic limitations and two in-clinic visits.Most of the recruited subjects had mild AD. Recruitment at hospital (outpatient clinics and wards) results in participants with moderate-to-severe disease severity. Online recruitment could be a worthy supplement to traditional recruitment to allow recruitment of participants from the entire disease severity scale.In conclusion, online patient recruitment using Facebook appears to be an effective method to recruit subjects with AD, both from a time and a cost perspective. The majority of recruited subjects were young females with mild AD.

Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study

“…However, the proportion of CR was superior in our series (47.4%) than that reported in clinical trials (32%) [6,14,15]. Similarly, other retrospective and real-world studies have shown better ORR results when compared with clinical trials [10][11][12][13]16]. This discrepancy may be due to different standards in evaluation and specially to the reliance on clinical examination instead of others like imaging by the dermatologist in real-life settings.…”

“…Recently, several groups have addressed the effectiveness, safety, and utilization of vismodegib in clinical routine [9][10][11][12][13]. Herms et al [9] specifically studied the follow-up of patients with complete remission of laBCC after vismodegib discontinuation in a group of 116 patients.…”

“…The relapse-free survival at 36 months was 35.4%. Some authors have also searched for predictive factors of relapse and assessed the response to secondary treatment options in these patients [9, 11, 13].…”

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness

“…Infiltrative type BCC was the most frequent histopathological subtype, accounting for 34.8% of all aBCC diagnoses. The high prevalence of this histopathological subtype has been reported also in pivotal trials and real-life studies on aBCC [7, 9–11, 18], where a similar association between high-risk histology and decreased tumor response has been described [19]. Occurrence of >2 AEs was also significantly associated with a higher probability of nonresponse to HHI.…”

“…Patients experiencing multiple AEs might undergo dose reduction or treatment discontinuation, which may affect tumor response outcomes. To this regard, some authors reported an association between intermittent dosing and nonresponse to HHI [18,20], while others claimed an unchanged efficacy profile [21][22][23].…”